Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease

被引:44
作者
Canbay, Ali [1 ]
Kachru, Nandita [2 ]
Haas, Jennifer Scarlet [3 ]
Sowa, Jan-Peter [1 ]
Meise, Dominic [3 ]
Ozbay, Ahmet Burak [2 ]
机构
[1] Ruhr Univ, Dept Internal Med, Bochum, Germany
[2] Gilead Sci Inc, Hlth Econ Outcomes Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[3] Xcenda GmbH, Hannover, Germany
关键词
STEATOHEPATITIS NASH; HEPATOCELLULAR-CARCINOMA; REAL-WORLD; CIRRHOSIS; BURDEN; NAFLD; RISK; FIBROSIS; TRANSPLANTATION; EPIDEMIOLOGY;
D O I
10.1111/apt.16016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. Aims To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a large, real-world cohort of German NAFLD patients. Methods Claims data from the German Institut fur angewandte Gesundheitsforschung database between 2011 and 2016 were analyzed retrospectively. Adult patients diagnosed with NAFLD and/or NASH were categorised as NAFLD, NAFLD non-progressors, compensated cirrhosis, decompensated cirrhosis, liver transplant or hepatocellular carcinoma (HCC). The longitudinal probability of mortality and incidence of progression were calculated for disease severity cohorts and multivariable analyses performed for adjusted mortality. Results Among 4 580 434 patients in the database, prevalence of NAFLD was 4.7% (n = 215 655). Of them, 36.8% were non-progressors, 0.2% compensated cirrhosis, 9.6% decompensated cirrhosis, 0.0005% liver transplant and 0.2% HCC. Comorbidity rates were significantly higher in compensated cirrhosis, decompensated cirrhosis and HCC compared with non-progressors. The longitudinal probability of mortality for non-progressors, compensated cirrhosis, decompensated cirrhosis and HCC was 3.6%, 18.7%, 28.8% and 68%, respectively. Independent predictors of mortality included cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity and renal impairment. The cumulative incidence of progression in NAFLD and compensated cirrhosis patients was 10.7% and 16.7%, respectively, over 5 years of follow-up. Conclusion NAFLD patients were severely under-diagnosed and had a high probability of mortality that increased with disease progression. Early identification and effective management to halt or reverse fibrosis are essential to prevent progression.
引用
收藏
页码:1185 / 1194
页数:10
相关论文
共 38 条
  • [1] Non-alcoholic fatty liver disease in 2015
    Ahmed, Monjur
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (11) : 1450 - 1459
  • [2] Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
    Alexander, Myriam
    Loomis, A. Katrina
    van der Lei, Johan
    Duarte-Salles, Talita
    Prieto-Alhambra, Daniel
    Ansell, David
    Pasqua, Alessandro
    Lapi, Francesco
    Rijnbeek, Peter
    Mosseveld, Mees
    Waterworth, Dawn M.
    Kendrick, Stuart
    Sattar, Naveed
    Alazawi, William
    [J]. BMC MEDICINE, 2019, 17 (1)
  • [3] Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
    Alexander, Myriam
    Loomis, A. Katrina
    Fairburn-Beech, Jolyon
    van der Lei, Johan
    Duarte-Salles, Talita
    Prieto-Alhambra, Daniel
    Ansell, David
    Pasqua, Alessandro
    Lapi, Francesco
    Rijnbeek, Peter
    Mosseveld, Mees
    Avillach, Paul
    Egger, Peter
    Kendrick, Stuart
    Waterworth, Dawn M.
    Sattar, Naveed
    Alazawi, William
    [J]. BMC MEDICINE, 2018, 16
  • [4] Characteristics and external validity of the German Health Risk Institute (HRI) Database
    Andersohn, Frank
    Walker, Jochen
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (01) : 106 - 109
  • [5] Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
    Angulo, Paul
    Kleiner, David E.
    Dam-Larsen, Sanne
    Adams, Leon A.
    Bjornsson, Einar S.
    Charatcharoenwitthaya, Phunchai
    Mills, Peter R.
    Keach, Jill C.
    Lafferty, Heather D.
    Stahler, Alisha
    Haflidadottir, Svanhildur
    Bendtsen, Flemming
    [J]. GASTROENTEROLOGY, 2015, 149 (02) : 389 - +
  • [6] Practical recommendations for reporting Fine-Gray model analyses for competing risk data
    Austin, Peter C.
    Fine, Jason P.
    [J]. STATISTICS IN MEDICINE, 2017, 36 (27) : 4391 - 4400
  • [7] The burden of liver disease in Europe: A review of available epidemiological data
    Blachier, Martin
    Leleu, Henri
    Peck-Radosavljevic, Markus
    Valla, Dominique-Charles
    Roudot-Thoraval, Francoise
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 (03) : 593 - 608
  • [8] Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data
    Canbay, Ali
    Kachru, Nandita
    Meise, Dominic
    Haas, Jennifer Scarlet
    Ozbay, Ahmet Burak
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E325 - E326
  • [9] NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?
    Canbay, Ali
    Sowa, Jan-Peter
    Syn, Wing-Kin
    Treckmann, Juergen
    [J]. VISCERAL MEDICINE, 2016, 32 (04) : 234 - 238
  • [10] Chalasani NP, 2017, HEPATOLOGY, V66, p303A